Pharmacogenomics · 2014 · 30 citations · 49 references
MedicineGeneticsMolecular GeneticsHuman GeneticsPharmacogeneticsPharmacogenomicsCopy Number Variant AnalysisGenotype-phenotype Association AnalysisPopulation PharmacogeneticsPopulation PharmacogenomicsAllele Frequency ComparisonCyp2d6 GenotypeCyp2d6 GenotypingCyp2d6 PharmacogeneticsCyp2d6 PhenotypingCytochrome P450 Genetic PolymorphismDrug Metabolism PolymorphismsReal-time Polymerase Chain Reaction (Pcr)
AIM: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficiency; therefore, we determined the CYP2D6 allele distribution in eight Amerindian groups from northwestern Mexico and compared them with the frequencies in Mexican Mestizos. MATERIALS & METHODS: A total of 508 Amerindians were studied. Genotyping of CYP2D6*5 and multiplication alleles was performed by long-range PCR, while CYP2D6*2, *3, *4, *6, *10, *17, *29, *35, *41 and copy number were evaluated by real-time PCR. RESULTS: The most frequent alleles were CYP2D6*2 (0.05-0.28), CYP2D6*4 (0.003-0.21) and multiplications (0.043-0.107). CYP2D6*5, *6, * 10 and *41 were not observed in the majority of Amerindians, and CYP2D6*3, *17, *35 and *29 were not detected. The poor metabolizer genotype ( *4/*5) was lower (0.2%) in Amerindians than in Mestizos (5%); conversely, the ultrarapid metabolizer genotype was higher (12.6%) in indigenous groups than in Mestizos (7%). CONCLUSION: Our data show a lower frequency of CYP2D6 inactive alleles and a higher frequency of duplication/multiplication of CYP2D6 active alleles in indigenous populations that in Mestizos. Original submitted 14 August 2013; Revision submitted 7 October 2013.
49
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
Shufeng Zhou · Clinical Pharmacokinetics · 2009 · 759 citations
Medicine, Genetics, Pharmacology +14
Inger Johansson, Mikael Oscarson, Qun‐Ying Yue et al. · Molecular Pharmacology · 1994 · 430 citations